Brief: Inventiva End-June Net Operating Loss Widens To EUR 33.5 Mln

Inventiva SA

22/09/2022 07:43

Sept 22 (Reuters) - INVENTIVA SA  IVAA.PA :
    * INVENTIVA REPORTS ITS 2022 FIRST-HALF FINANCIAL RESULTS
AND
PROVIDES A CORPORATE UPDATE
    * CASH POSITION AT EUR 87.2 MLN AS OF JUNE 30, 2022
    * REVENUES FOR FIRST HALF OF 2022 REACHED EUR 0.1 MLN
    * R&D EXPENSES FOR FIRST HALF OF 2022 AMOUNTED TO EUR 29.9
MLN
    * COMPANY'S NET LOSS STOOD AT (EUR 29.5) MLN IN FIRST HALF
OF 2022
    * PUBLICATION OF TOPLINE RESULTS OF PHASE IIA LEGEND OF
LANIFIBRANOR IN COMBINATION WITH EMPAGLIFLOZIN IN PATIENTS WITH
NASH AND T2D - PLANNED FOR SECOND HALF OF 2023
    * LAST PATIENT FIRST VISIT OF PHASE III NATIV3 CLINICAL
TRIAL
EVALUATING LANIFIBRANOR IN NASH - NOW TARGETED FOR SECOND HALF
OF 2023
    * PUBLICATION OF RESULTS OF INVESTIGATOR-INITIATED STUDY
WITH
LANIFIBRANOR IN PATIENTS WITH NAFLD AND T2D - NOW PLANNED FOR Q1
OF 2023
    * STUDY COMPLETION OF PHASE IIB TRIAL WITH CEDIROGANT IN
PATIENTS
WITH PSORIASIS CONDUCTED BY ABBVIE - PLANNED FOR FIRST HALF OF
2023
    * ESTIMATES THAT ITS EXISTING CASH, CASH EQUIVALENTS AND
SHORT-TERM DEPOSITS SHOULD ALLOW COMPANY TO FUND ITS OPERATIONS
THROUGH Q4 2023
    * ESTIMATES THAT ITS EXISTING CASH, CASH EQUIVALENTS AND
SHORT-TERM DEPOSITS SHOULD ALLOW COMPANY TO FUND ITS OPERATIONS
THROUGH Q4 2023
    * END-JUNE NET OPERATING LOSS EUR 33.5 MLN VS LOSS EUR 23.6
MLN YR
AGO

        
 Source text for Eikon:  ID:nGNXbY8vZn 
 Further company coverage:  IVAA.PA  
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))